Response to Immunotherapy Linked With Improved Liver Function in Advanced HCC
July 22nd 2024Although the amount of real-world evidence demonstrating the safety and efficacy of immune checkpoint inhibitors in advanced hepatocellular carcinoma (HCC) has been growing, data on liver function evolution as a prognostic factor for overall survival are lacking.
Read More
Key Considerations for Optimizing B-VEC in Dystrophic Epidermolysis Bullosa
July 22nd 2024Beremagene geperpavec-svdt (B-VEC) entered the market in 2023 as the first approved corrective treatment for dystrophic epidermolysis bullosa (DEB), a rare genetic disease affecting the skin and nails that is caused by mutations in the COL7A1 gene.
Read More
Understanding Coverage, Financing, and Future Trends of Gene Therapy in Employer Health Plans
July 21st 2024The Greater Philadelphia Business Coalition on Health webinar series provided an in-depth framework for the advantages of including cell and gene therapy coverage in employer health plans, as well as the challenges brought by manufacturing complexities and the need to address accessibility to treatment.
Read More
New Study Suggests Alopecia After COVID-19 Vaccine Rare but Possible
July 18th 2024A literature review found a link between COVID-19 vaccination and alopecia, with most cases experiencing hair loss within 1 month after the first dose. However, the small sample size and limited data call for further investigation.
Read More
Misleading ads are under scrutiny for their role in signing up consumers for Affordable Care Act (ACA) coverage without their permission; Sen Elizabeth Warren (D, Massachusetts) said there are enough votes in the Senate to suspend the filibuster to codify Roe v Wade in 2025 with a Democratic majority; women with endometriosis have about a fourfold risk of developing ovarian cancer.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen